NCT06683846View on ClinicalTrials.gov

Ivonescimab in the Treatment of Multiple Advanced Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Pheochromocytoma/ParagangliomaRhabdomyosarcomaPaget Disease, ExtramammaryRenal AngiomyolipomaPerivascular Epithelioid Cell Tumor, MalignantSarcomaUrachal CancerNeuroendocrine CancerBasal Cell CarcinomasSarcomatoid CarcinomaPenile CancerAdrenal Cortical CancerGerm Cell Cancer MetastaticNon-Clear Cell Renal Cell CarcinomaProstate CancersClear Cell Renal CancerUrothelial CarcinomaKidney CancerRare Tumors
Interventions
DRUG

Ivocizumab

Administered via intravenous (IV) infusion

Trial Locations (1)

200032

RECRUITING

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER